Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation
July 6, 2022
These preclinical results support the unique efficacy and safety profile of abemaciclib observed in clinical trials.”BUFFALO, NY- July 6, 2022 – Researchers from Eli Lilly and Company ... read more